Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001221113 | SCV001393137 | pathogenic | Saldino-Mainzer syndrome | 2024-11-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp80*) in the IFT140 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IFT140 are known to be pathogenic (PMID: 22503633, 23418020, 24009529, 26216056). This variant is present in population databases (no rsID available, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with retinitis pigmentosa (internal data). ClinVar contains an entry for this variant (Variation ID: 949617). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002497752 | SCV002813921 | likely pathogenic | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-05-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004753238 | SCV005357126 | pathogenic | IFT140-related disorder | 2024-08-30 | no assertion criteria provided | clinical testing | The IFT140 c.240G>A variant is predicted to result in premature protein termination (p.Trp80*). To our knowledge, this variant has not been reported in a clinically affected patient yet in the literature. This variant is reported in 0.0065% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in IFT140 are expected to be pathogenic. This variant is interpreted as pathogenic. |